We are live on ! Find out more
PBLA

Panbela Therapeutics, Inc. Common Stock
PBLA

Delisted

PBLA was delisted on the 6th of March, 2024.

Back to rankings

12 hedge funds and large institutions have $801K invested in Panbela Therapeutics, Inc. Common Stock in 2022 Q3 according to their latest regulatory filings, with 7 funds opening new positions, 1 increasing their positions, reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

622% more capital invested

Capital invested by funds: $111K → $801K (+$690K)

250% more first-time investments, than exits

New positions opened: 7 | Existing positions closed: 2

71% more funds holding

Funds holding: 7 → 12 (+5)

Holders
12
Holders Change
+5
Holders Change %
+71.43%
% of All Funds
0.21%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
7
Increased
1
Reduced
–
Closed
2
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
AC
Armistice Capital
New York
+$1.91M
2
Vanguard Group
Vanguard Group
Pennsylvania
+$189K
3
UBS Group
UBS Group
Switzerland
+$168K
4
CS
Clear Street
New York
+$105K
5
VF
Virtu Financial
New York
+$62.9K

Top Sellers

Rank Fund Capital Flow
1
Susquehanna International Group
Susquehanna International Group
Pennsylvania
-$12K
2
E
Ergoteles
New York
-$11K
3
Citadel Advisors
Citadel Advisors
Florida
-$7K
Name Holding Trade Value Shares
Change 		Change in
Stake
AC
1
Armistice Capital
New York
$588K +$1.91M +91 New
Vanguard Group
2
Vanguard Group
Pennsylvania
$60K +$189K +9 New
UBS Group
3
UBS Group
Switzerland
$51K +$168K +8 New
CS
4
Clear Street
New York
$30K +$105K +5 New
VF
5
Virtu Financial
New York
$19K +$62.9K +3 New
BAMG
6
Brand Asset Management Group
Missouri
$15K – – –
Morgan Stanley
7
Morgan Stanley
New York
$12K +$21K +1 +100%
BSW
8
Buckingham Strategic Wealth
Missouri
$7K – – –
OFG
9
Oxford Financial Group
Indiana
$5K +$21K +1 New
Verition Fund Management
10
Verition Fund Management
Connecticut
$5K +$21K +1 New
TRCT
11
Tower Research Capital (TRC)
New York
$4K – – –
Geode Capital Management
12
Geode Capital Management
Massachusetts
$3K – – –
Bank of America
13
Bank of America
North Carolina
$1K – – –
Osaic Holdings
14
Osaic Holdings
Arizona
$1K – – –
E
15
Ergoteles
New York
– -$11K -1 Closed
Susquehanna International Group
16
Susquehanna International Group
Pennsylvania
– -$12K -1 Closed
Citadel Advisors
17
Citadel Advisors
Florida
– -$7K – –

PBLA Hedge Fund Activity: Q3 2022 in Review

12 of the 5,806 institutional investors tracked by Wall St. Rank reported a position in Panbela Therapeutics, Inc. Common Stock (PBLA) for Q3 2022, worth a combined $801K — up 622% from $111K a quarter earlier.

Buyers outnumbered sellers: 7 funds opened new PBLA positions and 2 closed out — a net gain of 5 holders — while 1 added to existing stakes and 0 trimmed.

The largest buyer was Armistice Capital, opening a new position worth an estimated $1.91M. The largest seller was Susquehanna International Group, exiting entirely with an estimated $12K sold.

  • 12 institutional investors held Panbela Therapeutics, Inc. Common Stock (PBLA) as of Q3 2022, up from 7 in Q2 2022.
  • Funds reported $801K of Panbela Therapeutics, Inc. Common Stock stock for Q3 2022, up 622% quarter-over-quarter.
  • 7 funds opened new Panbela Therapeutics, Inc. Common Stock positions in Q3 2022 and 2 closed out, a net change of +5 holders.
  • The largest Panbela Therapeutics, Inc. Common Stock buyer in Q3 2022 was Armistice Capital, an estimated $1.91M added.
  • The largest Panbela Therapeutics, Inc. Common Stock seller in Q3 2022 was Susquehanna International Group, an estimated $12K sold.

Based on aggregated 13F filings for Q3 2022.